Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 8, Pages 2278
Publisher
MDPI AG
Online
2020-08-14
DOI
10.3390/cancers12082278
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Updated Results from the German Mpnsg-0212 Combination Trial: Ruxolitinib Plus Pomalidomide in Myelofibrosis with Anemia
- (2020) Frank Stegelmann et al. BLOOD
- Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience
- (2020) Elena Maria Elli et al. BLOOD
- Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis
- (2020) Claire N Harrison et al. BLOOD
- A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia
- (2020) Aaron T. Gerds et al. BLOOD
- A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia
- (2020) Prithviraj Bose et al. LEUKEMIA
- Single-cell analysis based dissection of clonality in myelofibrosis
- (2020) Elena Mylonas et al. Nature Communications
- Smad2/3‐pathway ligand trap luspatercept enhances erythroid differentiation in murine β‐thalassaemia by increasing GATA‐1 availability
- (2020) Pedro A. Martinez et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes
- (2020) Jan Stetka et al. Cancers
- PRMT5 inhibition modulates E2F1 methylation and gene regulatory networks leading to therapeutic efficacy in JAK2V617F mutant MPN
- (2020) Friederike Pastore et al. Cancer Discovery
- Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
- (2020) Flávia Alves Verza et al. Cancers
- Luspatercept for the treatment of anemia in myelodysplastic syndromes (MDS) and primary myelofibrosis (PMF)
- (2019) Pierre Fenaux et al. BLOOD
- A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis
- (2019) Prithviraj Bose et al. LEUKEMIA & LYMPHOMA
- Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling
- (2019) Daniel A. C. Fisher et al. LEUKEMIA
- Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms
- (2019) Simona Stivala et al. JOURNAL OF CLINICAL INVESTIGATION
- Aurora kinase A inhibition provides clinical benefit, normalizes megakaryocytes and reduces bone marrow fibrosis in patients with myelofibrosis
- (2019) Naseema Gangat et al. CLINICAL CANCER RESEARCH
- Results from HARMONY: an open-label, multicentre, 2-arm, phase 1b, dose-finding study assessing the safety and efficacy of the oral combination of ruxolitinib and buparlisib in patients with myelofibrosis
- (2019) Simon T. Durrant et al. HAEMATOLOGICA
- LOXL2—A New Target in Antifibrogenic Therapy?
- (2019) Angela Puente et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis
- (2019) Novella Pugliese et al. Cancer Medicine
- Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis
- (2019) Massimo Breccia et al. ANNALS OF HEMATOLOGY
- Oral Idasanutlin in Patients with Polycythemia Vera
- (2019) John Mascarenhas et al. BLOOD
- Activation of JAK/STAT signaling in megakaryocytes sustains myeloproliferation in vivo
- (2019) Brittany Woods et al. CLINICAL CANCER RESEARCH
- Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms
- (2019) Xing Hao et al. INVESTIGATIONAL NEW DRUGS
- Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells
- (2019) Cing Siang Hu et al. BLOOD
- HDAC11 Deficiency or Inhibition Disrupts Oncogene-Induced Stress Hematopoiesis in Myeloproliferative Neoplasms
- (2019) Lanzhu Yue et al. BLOOD
- Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study
- (2019) Raajit K. Rampal et al. BLOOD
- RMC-4550, an Allosteric Inhibitor of SHP2, Displays Therapeutic Efficacy in Pre-Clinical Models of Myeloproliferative Neoplasms
- (2019) Garima Pandey et al. BLOOD
- Prognostic impact of RAS-pathway mutations in patients with myelofibrosis
- (2019) Fabio P. S. Santos et al. LEUKEMIA
- Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations
- (2019) Rebecca J. Austin et al. LEUKEMIA
- LSD1/KDM1A, a Gate-Keeper of Cancer Stemness and a Promising Therapeutic Target
- (2019) Panagiotis Karakaidos et al. Cancers
- Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib
- (2019) Elena Maria Elli et al. Frontiers in Oncology
- Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.
- (2019) Anders Lindholm Sørensen et al. HAEMATOLOGICA
- A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
- (2019) J. Mascarenhas et al. LEUKEMIA RESEARCH
- Glycogen Synthase Kinase-3β Inhibition with 9-ING-41 Attenuates the Progression of Pulmonary Fibrosis
- (2019) Ann Jeffers et al. Scientific Reports
- The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib
- (2018) Elena Crisà et al. BRITISH JOURNAL OF HAEMATOLOGY
- Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms
- (2018) Maria Kleppe et al. CANCER CELL
- Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients
- (2018) Nicola Polverelli et al. HEMATOLOGICAL ONCOLOGY
- Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
- (2018) Hans Michael Kvasnicka et al. Journal of Hematology & Oncology
- JAK2V617F Megakaryocytes Promote Hematopoietic Stem/Progenitor Cell Expansion in Mice through Thrombopoietin/MPL signaling
- (2018) Yu Zhang et al. STEM CELLS
- Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2
- (2018) Shinya Ishida et al. Oncotarget
- Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management
- (2018) Ayalew Tefferi AMERICAN JOURNAL OF HEMATOLOGY
- A phase II study of ruxolitinib in combination with azacytidine in patients with myelofibrosis
- (2018) Lucia Masarova et al. BLOOD
- A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
- (2018) Stephen Couban et al. Journal of Hematology & Oncology
- Perspectives on interferon-alpha in the treatment of Polycythemia vera and related Myeloproliferative neoplasms: minimal residual disease and cure?
- (2018) Hans Carl Hasselbalch et al. Seminars in Immunopathology
- Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients
- (2018) Francesca Palandri et al. LEUKEMIA RESEARCH
- Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells
- (2017) D T Saenz et al. LEUKEMIA
- Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis
- (2017) K. Gowin et al. LEUKEMIA RESEARCH
- Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics
- (2017) Stuart W. Ember et al. MOLECULAR CANCER THERAPEUTICS
- Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera
- (2017) T Tsuruta-Kishino et al. ONCOGENE
- How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes
- (2017) Fulvio Massaro et al. Expert Review of Hematology
- BET Proteins as Targets for Anticancer Treatment
- (2017) Anastasios Stathis et al. Cancer Discovery
- Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A/ CIP2A axis
- (2017) Niccolò Bartalucci et al. Oncotarget
- Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis
- (2017) Francesca Palandri et al. Oncotarget
- The combination treatment regimen of ruxolitinib with low-dose mercaptopurine or cytarabine in frail patients with blast-phase myelofibrosis
- (2016) Mikhail Fominykh et al. BRITISH JOURNAL OF HAEMATOLOGY
- Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis
- (2016) Ilaria Ceglia et al. EXPERIMENTAL HEMATOLOGY
- A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
- (2016) Vikas Gupta et al. HAEMATOLOGICA
- Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
- (2016) John O. Mascarenhas et al. HAEMATOLOGICA
- Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis
- (2016) Srdan Verstovsek et al. JOURNAL OF EXPERIMENTAL MEDICINE
- A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence
- (2016) A Tefferi et al. LEUKEMIA
- BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells
- (2016) D T Saenz et al. LEUKEMIA
- JAK2V617F allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy
- (2016) G Barosi et al. LEUKEMIA
- JAK2V617F-mutant megakaryocytes contribute to hematopoietic stem/progenitor cell expansion in a model of murine myeloproliferation
- (2016) H Zhan et al. LEUKEMIA
- Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia
- (2016) D A C Fisher et al. LEUKEMIA
- Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
- (2016) C N Harrison et al. LEUKEMIA
- A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
- (2016) Vikas Gupta et al. HAEMATOLOGICA
- Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
- (2016) John O. Mascarenhas et al. HAEMATOLOGICA
- Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results
- (2015) Francisco Cervantes et al. ANNALS OF HEMATOLOGY
- Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib
- (2015) K. P. Patel et al. BLOOD
- The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
- (2015) M. Deininger et al. BLOOD
- Combination therapy with ruxolitinib plus intensive treatment strategy is feasible in patients with blast-phase myeloproliferative neoplasms
- (2015) Raynier Devillier et al. BRITISH JOURNAL OF HAEMATOLOGY
- The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond
- (2015) Nicole Stopa et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I
- (2015) Ruben A. Mesa et al. Clinical Lymphoma Myeloma & Leukemia
- Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis
- (2015) N. Daver et al. HAEMATOLOGICA
- A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
- (2015) A. M. Vannucchi et al. HAEMATOLOGICA
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- Megakaryocytic hyperplasia in myeloproliferative neoplasms is driven by disordered proliferative, apoptotic and epigenetic mechanisms
- (2015) Jacques A J Malherbe et al. JOURNAL OF CLINICAL PATHOLOGY
- Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
- (2015) Catriona Jamieson et al. Journal of Translational Medicine
- Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
- (2015) S Verstovsek et al. LEUKEMIA
- Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition
- (2015) Qiang Jeremy Wen et al. NATURE MEDICINE
- A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
- (2015) Ayalew Tefferi et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
- (2015) A Pardanani et al. Blood Cancer Journal
- The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells
- (2015) Lucia Mazzacurati et al. Oncotarget
- Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis
- (2015) N. Daver et al. HAEMATOLOGICA
- A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
- (2015) A. M. Vannucchi et al. HAEMATOLOGICA
- Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
- (2015) S. Verstovsek et al. HAEMATOLOGICA
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- JAK2V617F Drives Mcl-1 Expression and Sensitizes Hematologic Cell Lines to Dual Inhibition of JAK2 and Bcl-xL
- (2015) Jun Guo et al. PLoS One
- Combination of PIM and JAK2 inhibitors synergistically suppresses cell proliferation and overcomes drug resistance of myeloproliferative neoplasms
- (2015) Shih-Min A. Huang et al. Oncotarget
- Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors
- (2014) Stuart W. J. Ember et al. ACS Chemical Biology
- Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms
- (2014) Neha Bhagwat et al. BLOOD
- Lysine-specific demethylase 1 (LSD1) in hematopoietic and lymphoid neoplasms
- (2014) D. Niebel et al. BLOOD
- Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
- (2014) R. Rampal et al. BLOOD
- Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms
- (2014) Anne Mwirigi et al. BRITISH JOURNAL OF HAEMATOLOGY
- New and emerging HDAC inhibitors for cancer treatment
- (2014) Alison C. West et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies
- (2014) Raoul Tibes et al. Journal of Hematology & Oncology
- Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
- (2014) Pietro Ciceri et al. Nature Chemical Biology
- Targeting bromodomains: epigenetic readers of lysine acetylation
- (2014) Panagis Filippakopoulos et al. NATURE REVIEWS DRUG DISCOVERY
- Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms
- (2014) Raajit Rampal et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis
- (2014) P. S. Winter et al. Science Signaling
- The expression of lysyl-oxidase gene family members in myeloproliferative neoplasms
- (2013) T. Tadmor et al. AMERICAN JOURNAL OF HEMATOLOGY
- Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
- (2013) A. Tefferi et al. BLOOD
- Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon- in a murine model of polycythemia vera
- (2013) A. Mullally et al. BLOOD
- JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN
- (2013) S. Hasan et al. BLOOD
- The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
- (2013) Srdan Verstovsek et al. BRITISH JOURNAL OF HAEMATOLOGY
- JAK1/2 and Pan-Deacetylase Inhibitor Combination Therapy Yields Improved Efficacy in Preclinical Mouse Models of JAK2V617F-Driven Disease
- (2013) E. Evrot et al. CLINICAL CANCER RESEARCH
- Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms
- (2013) Niccolò Bartalucci et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- AKT is a therapeutic target in myeloproliferative neoplasms
- (2013) I Khan et al. LEUKEMIA
- BET protein inhibition shows efficacy against JAK2V617F-driven neoplasms
- (2013) B S Wyspiańska et al. LEUKEMIA
- Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells
- (2013) W. Fiskus et al. MOLECULAR CANCER THERAPEUTICS
- mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms
- (2013) Costanza Bogani et al. PLoS One
- Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
- (2013) Michaela Waibel et al. Cell Reports
- Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation
- (2013) Marc A Kerenyi et al. eLife
- Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon- 2a specifically targets JAK2V617F-positive polycythemia vera cells
- (2012) M. Lu et al. BLOOD
- Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
- (2012) A. Eghtedar et al. BLOOD
- Efficacy of vorinostat in a murine model of polycythemia vera
- (2012) H. Akada et al. BLOOD
- The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells
- (2012) William J. Harris et al. CANCER CELL
- Identification of Regulators of Polyploidization Presents Therapeutic Targets for Treatment of AMKL
- (2012) Qiang Wen et al. CELL
- Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation
- (2012) A Sprüssel et al. LEUKEMIA
- Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
- (2012) Priya Koppikar et al. NATURE
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- TNF facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms
- (2011) A. G. Fleischman et al. BLOOD
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
- (2011) Jake E. Delmore et al. CELL
- Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells
- (2011) W. Fiskus et al. CLINICAL CANCER RESEARCH
- Control of Megakaryocyte Expansion and Bone Marrow Fibrosis by Lysyl Oxidase
- (2011) Alexia Eliades et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
- (2011) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- JAK2V617F negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms
- (2011) M Nakatake et al. ONCOGENE
- Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling
- (2011) David A. Proia et al. PLoS One
- Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903
- (2010) R. A. Mesa et al. BLOOD
- MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF- B-dependent lymphoma
- (2010) M. A. Milhollen et al. BLOOD
- Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia
- (2010) R. T. Swords et al. BLOOD
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells
- (2010) Ann Mullally et al. CANCER CELL
- HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans
- (2010) Sachie Marubayashi et al. JOURNAL OF CLINICAL INVESTIGATION
- A phase-2 trial of low-dose pomalidomide in myelofibrosis
- (2010) K H Begna et al. LEUKEMIA
- Therapeutic options for patients with myelofibrosis in blast phase
- (2010) John Mascarenhas et al. LEUKEMIA RESEARCH
- Selective inhibition of BET bromodomains
- (2010) Panagis Filippakopoulos et al. NATURE
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase1/-2 study of Pomalidomide in myelofibrosis
- (2009) Ruben A. Mesa et al. AMERICAN JOURNAL OF HEMATOLOGY
- Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells
- (2009) Y. Wang et al. BLOOD
- Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis
- (2009) Alfonso Quintás-Cardama et al. JOURNAL OF CLINICAL ONCOLOGY
- Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
- (2009) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
- (2009) Teresa A. Soucy et al. NATURE
- The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms
- (2008) C. S. Tam et al. BLOOD
- The many roles of histone deacetylases in development and physiology: implications for disease and therapy
- (2008) Michael Haberland et al. NATURE REVIEWS GENETICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started